{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:47:58Z","timestamp":1793836078102,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ophtha.2020.12.036","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T16:13:29Z","timestamp":1610122409000},"page":"1180-1187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["Age Effect on Treatment Responses to 0.05%, 0.025%, and 0.01% Atropine"],"prefix":"10.1016","volume":"128","author":[{"given":"Fen Fen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Hon Kei","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu Min","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Wai","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4365-3218","authenticated-orcid":false,"given":"Alvin L.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-6907","authenticated-orcid":false,"given":"Clement C.","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Pui","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2156-1486","authenticated-orcid":false,"given":"Jason C.","family":"Yam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9827","key":"10.1016\/j.ophtha.2020.12.036_bib1","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0140-6736(12)60272-4","volume":"379","author":"Morgan","year":"2012","journal-title":"Myopia. Lancet"},{"issue":"5","key":"10.1016\/j.ophtha.2020.12.036_bib2","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ophtha.2020.12.036_bib3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/aos.14350","article-title":"High prevalence of myopia in children and their parents in Hong Kong Chinese Population: the Hong Kong Children Eye Study","volume":"98","author":"Yam","year":"2020","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2020.12.036_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1167\/iovs.61.4.49","article-title":"The complications of myopia: a review and meta-analysis","volume":"61","author":"Haarman","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ophtha.2020.12.036_bib5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ophtha.2018.10.029","article-title":"Potential lost productivity resulting from the global burden of myopia: systematic review, meta-analysis, and modeling","volume":"126","author":"Naidoo","year":"2019","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ophtha.2020.12.036_bib6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/APO.0000000000000256","article-title":"Low-concentration atropine eye drops for myopia progression","volume":"8","author":"Li","year":"2019","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"1","key":"10.1016\/j.ophtha.2020.12.036_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-Concentration Atropine for Myopia Progression (LAMP) Study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ophtha.2020.12.036_bib8","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-year clinical trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: phase 2 report","volume":"127","author":"Yam","year":"2020","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ophtha.2020.12.036_bib9","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.ophtha.2020.06.004","article-title":"Differential effects on ocular biometrics by 0.05%, 0.025%, and 0.01% atropine: Low-Concentration Atropine for Myopia Progression Study","volume":"127","author":"Li","year":"2020","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ophtha.2020.12.036_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ophtha.2020.12.036_bib11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/ceo.13736","article-title":"Western Australia Atropine for the Treatment of Myopia (WA-ATOM) Study: rationale, methodology and participant baseline characteristics","volume":"48","author":"Lee","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"issue":"9","key":"10.1016\/j.ophtha.2020.12.036_bib12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/jop.2015.0043","article-title":"Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia","volume":"31","author":"Clark","year":"2015","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ophtha.2020.12.036_bib13","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.oftal.2017.12.015","article-title":"Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness","volume":"93","author":"Diaz-Llopis","year":"2018","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"7","key":"10.1016\/j.ophtha.2020.12.036_bib14","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/bjophthalmol-2019-314819","article-title":"Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)-study protocol","volume":"104","author":"Azuara-Blanco","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.12.036_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.12688\/hrbopenres.12914.1","article-title":"Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol","volume":"2","author":"McCrann","year":"2019","journal-title":"HRB Open Res"},{"issue":"10","key":"10.1016\/j.ophtha.2020.12.036_bib16","first-page":"1657","article-title":"The diluted atropine for inhibition of myopia progression in Korean children","volume":"11","author":"Moon","year":"2018","journal-title":"Int J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2020.12.036_bib17","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.ajo.2015.01.029","article-title":"Risk factors for progressive myopia in the atropine therapy for myopia study","volume":"159","author":"Loh","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ophtha.2020.12.036_bib18","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/archopht.123.7.977","article-title":"Relationship of age, sex, and ethnicity with myopia progression and axial elongation in the correction of myopia evaluation trial","volume":"123","author":"Hyman","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2020.12.036_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/OPX.0b013e3182357f79","article-title":"Myopia progression rates in urban children wearing single-vision spectacles","volume":"89","author":"Donovan","year":"2012","journal-title":"Optom Vis Sci"},{"issue":"4","key":"10.1016\/j.ophtha.2020.12.036_bib20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/aje\/kwf215","article-title":"Statistical analysis of correlated data using generalized estimating equations: an orientation","volume":"157","author":"Hanley","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"11","key":"10.1016\/j.ophtha.2020.12.036_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaophthalmol.2020.3451","article-title":"Association of age at myopia onset with risk of high myopia in adulthood in a 12-year follow-up of a Chinese cohort","volume":"138","author":"Hu","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2020.12.036_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/jop.2011.0027","article-title":"The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren","volume":"27","author":"Wu","year":"2011","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2020.12.036_bib23","doi-asserted-by":"crossref","first-page":"01081","DOI":"10.3389\/fphar.2020.01081","article-title":"Analysis of factors that may affect the effect of atropine 0.01% on myopia control","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.ophtha.2020.12.036_bib24","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1167\/iovs.07-1492","article-title":"Minus-lens-stimulated accommodative amplitude decreases sigmoidally with age: a study of objectively measured accommodative amplitudes from age 3","volume":"49","author":"Anderson","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.ophtha.2020.12.036_bib25","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1097\/OPX.0000000000000037","article-title":"Maximum atropine dose without clinical signs or symptoms","volume":"90","author":"Cooper","year":"2013","journal-title":"Optom Vis Sci"},{"issue":"1","key":"10.1016\/j.ophtha.2020.12.036_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ophtha.2018.08.024","article-title":"The lowdown on low-concentration atropine for myopia progression","volume":"126","author":"Sankaridurg","year":"2019","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2020.12.036_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control","volume":"33","author":"Wu","year":"2019","journal-title":"Eye (Lond)"},{"issue":"11","key":"10.1016\/j.ophtha.2020.12.036_bib28","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","article-title":"Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial","volume":"138","author":"Wei","year":"2020","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642021000014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642021000014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:10:13Z","timestamp":1758982213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642021000014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0161642021000014"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.12.036","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Age Effect on Treatment Responses to 0.05%, 0.025%, and 0.01% Atropine","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.12.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}